CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

76-092

CHEMISTRY REVIEW(S)

ANDA APPROVAL SUMMARY

ANDA:76-092 DRUG PRODUCT: Ketamine HCl Inj. USP

FIRM: Bioniche Pharma

DOSAGE FORM: I.V. and I.M. STRENGTHS:

Strength	Strength units
50	mg

CGMP STATEMENT/EIR UPDATE STATUS:

CGMP statement (p.200) in original submission.

EIR for drug product manufacturer acceptable, 8/2/01.

Facilities included:

Manufacturing, testing, packaging, labeling, and stability testing:

Bioniche Teoranta, Inverin, Co. Galway, Ireland

[redacted]

BIO STUDY:

The waiver of in vivo bioequivalence study for, 50 mg/ml, filled in 10 ml vials of the test product is granted by the Division of Bioequivalence per Andre Jackson, Ph.D., 04/26/01.

VALIDATION - (DESCRIPTION OF DOSAGE FORM SAME AS FIRM'S):

Both drug substance and drug product compendial.

STABILITY - ARE CONTAINERS USED IN STUDY IDENTICAL TO THOSE IN CONTAINER SECTION?:

Ketamine hydrochloride injection USP, [redacted] is packaged in [redacted] type 1 glass vial and ketamine hydrochloride injection USP, 50 and [redacted] is packaged in 10 ml [redacted] type 1 glass vial.

Stability for the following included:

Lot #	Batch Size	Sample	Test Conditions
990317	[redacted]	Ketamine HCl injection USP	40°C/75% RH/3 months
990317	[redacted]	Ketamine HCl injection USP	25° -30°C/36 months

Container/Closure system:

All container/closure systems are as described in the Container/Closure section.

Expiration date: 36 months based on accelerated stability data.

LABELING:

Description in package insert satisfactory for molecular structure, molecular formula, formula weight, inactive ingredients, product description and package size.

Professional labeling - satisfactory, Chan Park, 11/05/01.

STERILIZATION VALIDATION (IF APPLICABLE):

SIZE OF BIO BATCH (FIRM'S SOURCE OF NDS OK?):

Bio batch: Ketamine HCl Inj. USP, Lot # 990317, batch size [redacted] stability data included.

DMF # [redacted] October 11,01 satisfactory, no amendments since then.

SIZE OF STABILITY BATCHES - (IF DIFFERENT FROM BIO BATCH, WERE THEY MANUFACTURED VIA THE SAME PROCESS?):

See above.

PROPOSED PRODUCTION BATCH - MANUFACTURING PROCESS THE SAME AS BIO/STABILITY? yes

An executed batch record for the [redacted] batch (bioequivalence/stability batch) included. A blank batch record was submitted in the application for [redacted] Proposed manufacturing processes are the same as the bio/stability batches.

1. CHEMISTRY REVIEW NO. 1 2. ANDA # 76-092

3. NAME AND ADDRESS OF APPLICANT

Bioniche Pharma
Attention: Albert Beraldo
383 Sovereign Road
London, ON, Canada
N6m 1A3
Tel: (519) 453-0641

4. LEGAL BASIS FOR SUBMISSION

RLD is Ketalar®, 50 mg base /mL, the subject of NDA No. 016812, by Parkedale.

Patent Data:

There are no unexpired patents for this product in the Orange Book Database.

Exclusivity Data:

There is no unexpired exclusivity for this product.

5. SUPPLEMENT(s)

N/A

6. PROPRIETARY NAME

N/A

7. NONPROPRIETARY NAME

Ketamine HCl Inj. USP

8. SUPPLEMENT(s) PROVIDE(s) FOR:

N/A

9. AMENDMENTS AND OTHER DATES:

Firm:
December 2~~4~~, 2000- Original submission
March 8, 2001

FDA:
Labeling review, pending
bio review, April 31, 2001-, acceptable
CMC review, unacceptable, May, 11, 2001

10. PHARMACOLOGICAL CATEGORY

Anesthetic

11. Rx or OTC

Rx

12. RELATED DMFs
NDA # 16964 Abbott Laboratories
DMF# [redacted]
DMF# [redacted]
DMF# [redacted]
DMF# [redacted]
DMF# [redacted]

13. DOSAGE FORM
I.V. and I.M.

14. POTENCY
50 mg

15. CHEMICAL NAME AND STRUCTURE
dl 2-(0-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride

16. RECORDS AND REPORTS
Labeling review, pending
Bio review, acceptable, April 31, 2001
CMC review, unacceptable, May 11, 2001

17. COMMENTS
Ketamine HCl is USP

Deficiency noted:
1. Labeling is pending
2. Bio review, acceptable, April 31, 2001
3. CMC review, unacceptable, May 11, 2001
4. DMF has checked out by J. Wong on February 2001

18. CONCLUSIONS AND RECOMMENDATIONS
Recommend not approvable letter to issue
Not approved

19. REVIEWER: Mahnaz Farahani Ph.D.
DATE COMPLETED: May 11, 2001

Redacted 12

Page(s) of trade secret and /or confidential commercial information

1. CHEMISTRY REVIEW NO. 2 2. ANDA # 76-092

3. NAME AND ADDRESS OF APPLICANT
Bioniche Pharma (Canada) Ltd.
Attention: Rhonda Noll
151 Dundas Street
Suit 507
London, ON,
Canada N6A 5R7
Tel: (800) 567-2028

4. LEGAL BASIS FOR SUBMISSION
RLD is Ketalar®, 50 mg base /mL, the subject of NDA No. 016812, by Parkedale.

Patent Data:

There are no unexpired patents for this product in the Orange Book Database.

Exclusivity Data:

There is no unexpired exclusivity for this product.

5. SUPPLEMENT(s)
N/A

6. PROPRIETARY NAME
N/A

7. NONPROPRIETARY NAME
Ketamine HCl Inj. USP

8. SUPPLEMENT(s) PROVIDE(s) FOR:
N/A

9. AMENDMENTS AND OTHER DATES:
Firm:
December 21, 2000- Original submission
September 25, 2001- Minor Amendment
May 23, 2001 - Amendment JM 1/4/02
FDA:
Labeling review, November 5, 2001 - acceptable
Bio review, April 31, 2001-, acceptable
CMC review, acceptable, 10/29/01
Micro review, November 27, 2001 - acceptable

10. PHARMACOLOGICAL CATEGORY
Anesthetic

11. Rx or OTC
Rx

12. RELATED DMFs
NDA # 16964 Abbott Laboratories
DMF# [redacted]
DMF# [redacted]
DMF# [redacted]
DMF# [redacted]
DMF# [redacted]

13. DOSAGE FORM
I.V. and I.M.

14. POTENCY
50 mg

15. CHEMICAL NAME AND STRUCTURE
dl 2-(0-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride

16. RECORDS AND REPORTS
Bio review, acceptable, April 31, 2001
Labeling review, acceptable, 11/5/01
CMC review, acceptable, 10/29/01
DMF has reviewed by Mahnaz Farahani on October 10/01 and found acceptable.

17. COMMENTS

18. CONCLUSIONS AND RECOMMENDATIONS
Approved

19. REVIEWER:
Mahnaz Farahani Ph.D.

DATE COMPLETED:
October 29, 2001

Redacted 11

Page(s) of trade secret and /or confidential commercial information